CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens.
作者信息
Quirt J, Gagnon R, Ellis A K, Kim H L
机构信息
McMaster University, Hamilton, Canada.
Laval University, Quebec City, Canada.
出版信息
Allergy Asthma Clin Immunol. 2018 Jan 9;14:1. doi: 10.1186/s13223-017-0225-6. eCollection 2018.
Abstract
摘要
相似文献
1
CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens.
Allergy Asthma Clin Immunol. 2018 Jan 9;14:1. doi: 10.1186/s13223-017-0225-6. eCollection 2018.
2
CSACI position statement: epinephrine auto-injectors and children < 15 kg.
Allergy Asthma Clin Immunol. 2015 Jun 12;11(1):20. doi: 10.1186/s13223-015-0086-9. eCollection 2015.
3
The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
Biol Pharm Bull. 2019;42(6):1030-1033. doi: 10.1248/bpb.b18-00857.
4
Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis.
Allergy Asthma Clin Immunol. 2015 Jun 10;11(1):19. doi: 10.1186/s13223-015-0085-x. eCollection 2015.
5
Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
Int Arch Allergy Immunol. 2017;174(1):26-34. doi: 10.1159/000479693. Epub 2017 Sep 27.
6
Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from allergen-release data.
Expert Rev Clin Immunol. 2019 Sep;15(9):921-928. doi: 10.1080/1744666X.2019.1649597. Epub 2019 Aug 12.
7
Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
J Allergy Clin Immunol. 2014 Jun;133(6):1608-14.e6. doi: 10.1016/j.jaci.2013.11.012. Epub 2013 Dec 31.
8
Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.
Postgrad Med. 2017 Aug;129(6):581-589. doi: 10.1080/00325481.2017.1308208. Epub 2017 Mar 27.
9
The Importance of Tablet Formulation on Allergen Release Kinetics and Efficiency: Comparison of Freeze-dried and Compressed Grass Pollen Sublingual Allergy Immunotherapy Tablet Formulations.
Clin Ther. 2019 Apr;41(4):742-753. doi: 10.1016/j.clinthera.2019.02.008. Epub 2019 Mar 16.
10
A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.
Postgrad Med. 2017 Aug;129(6):590-597. doi: 10.1080/00325481.2017.1302306. Epub 2017 Mar 22.
引用本文的文献
1
Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting.
Blood Res. 2024 Dec 18;59(1):42. doi: 10.1007/s44313-024-00048-0.
2
Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?
Allergy Asthma Clin Immunol. 2019 Apr 27;15:27. doi: 10.1186/s13223-019-0344-3. eCollection 2019.
3
The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option.
Allergy Asthma Clin Immunol. 2019 Apr 16;15:24. doi: 10.1186/s13223-018-0314-1. eCollection 2019.
本文引用的文献
1
Allergy immunotherapy: what is the evidence for cost saving?
Curr Opin Allergy Clin Immunol. 2014 Aug;14(4):363-70. doi: 10.1097/ACI.0000000000000084.
2
Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
J Eval Clin Pract. 2014 Jun;20(3):225-38. doi: 10.1111/jep.12112. Epub 2014 Jan 21.
3
Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials.
Clin Respir J. 2014 Apr;8(2):192-205. doi: 10.1111/crj.12058. Epub 2014 Mar 5.
4
Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Clin Exp Allergy. 2013 May;43(5):568-77. doi: 10.1111/cea.12100.
5
Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison.
J Allergy Clin Immunol. 2013 May;131(5):1361-6. doi: 10.1016/j.jaci.2013.02.013. Epub 2013 Apr 1.
6
Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review.
JAMA. 2013 Mar 27;309(12):1278-88. doi: 10.1001/jama.2013.2049.
7
Sub-lingual immunotherapy: world allergy organization position paper 2009.
World Allergy Organ J. 2009 Nov;2(11):233-81. doi: 10.1097/WOX.0b013e3181c6c379. Epub 2009 Nov 19.
8
The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients.
Allergy Asthma Clin Immunol. 2012 Jun 1;8(1):7. doi: 10.1186/1710-1492-8-7.
9
SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.
J Allergy Clin Immunol. 2012 Mar;129(3):717-725.e5. doi: 10.1016/j.jaci.2011.12.973. Epub 2012 Jan 29.
10
Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence.
J Allergy Clin Immunol. 2012 Apr;129(4):929-34. doi: 10.1016/j.jaci.2011.11.019. Epub 2012 Jan 11.
Zotero 插件